We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

11 hedge funds and large institutions have $1.69M invested in Northwest Biotherapeutics, Inc. Common stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% less capital invested

Capital invested by funds: $2.01M → $1.69M (-$319K)

21% less funds holding

Funds holding: 14 → 11 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SL
Sentinus LLC
Illinois
+$158K
2
MSAM
Moloney Securities Asset Management
Missouri
+$25.8K

Top Sellers

Rank Fund Capital Flow
1
AA
Ancora Advisors
Ohio
-$329K
2
EFG
Ethos Financial Group
Pennsylvania
-$13.9K
3
GWI
Grace & White Inc
New York
-$9.19K
Name Holding Trade Value Shares
Change 		Change in
Stake
SL
1
Sentinus LLC
Illinois
$1.4M +$158K +279,000 +13%
MSAM
2
Moloney Securities Asset Management
Missouri
$187K +$25.8K +45,500 +16%
OCG
3
Opus Capital Group
Ohio
$34K – – –
WJWM
4
Williams Jones Wealth Management
New York
$25K – – –
MCM
5
MAI Capital Management
Ohio
$11.4K – – –
LDB
6
Lee, Danner & Bass
Tennessee
$11K – – –
AA
7
AlphaMark Advisors
Kentucky
$8K – – –
AMG
8
Advisors Management Group
Wisconsin
$6K – – –
BCWM
9
Bartlett & Co Wealth Management
Ohio
$2.44K – – –
BC
10
Bartlett & Co
Ohio
$2K – – –
AA
11
Ancora Advisors
Ohio
– -$329K -526,000 Closed
EFG
12
Ethos Financial Group
Pennsylvania
– -$13.9K -22,200 Closed
GWI
13
Grace & White Inc
New York
– -$9.19K -14,705 Closed

NWBO Hedge Fund Activity: Q2 2023 in Review

11 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2023, worth a combined $1.69M — down 16% from $2.01M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of NWBO and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Sentinus LLC, adding an estimated $158K. The largest seller was Ancora Advisors, exiting entirely with an estimated $329K sold.

  • 11 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2023, down from 14 in Q1 2023.
  • Funds reported $1.69M of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2023, down 16% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2023 and 3 closed out, a net change of -3 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2023 was Sentinus LLC, an estimated $158K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2023 was Ancora Advisors, an estimated $329K sold.

Based on aggregated 13F filings for Q2 2023.